Trial Profile
A Phase 1b Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs ADXS 31164 (Primary)
- Indications Advanced breast cancer; Gastric cancer; Oesophageal cancer; Osteosarcoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Advaxis
- 04 Mar 2019 Status changed from active, no longer recruiting to completed.
- 13 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 13 Apr 2016 Status changed from active, no longer recruiting to recruiting.